Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain

Tapentadol, a step toward a solution

Keith A Candiotti, Melvin C. Gitlin

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: Opioids are among the most effective and potent analgesics currently available. Their utility in the management of pain associated with cancer, acute injury, or surgery is well recognized. However, extending the application of opioids to the management of chronic non-cancer pain has met with considerable resistance. This resistance is due in part to concerns related to gastrointestinal and central nervous system-related adverse events as well as issues pertaining to regulatory affairs, the development of tolerance, incorrect drug usage, and addiction. This review focuses on the incidence of opioid-related side effects and the patient and physician barriers to opioid therapy for chronic non-cancer pain. Tapentadol, a centrally acting analgesic with two mechanisms of action,-opioid agonism and norepinephrine reuptake inhibition, may be considered to be a partial solution to some of these issues. Methods: MEDLINE was searched for English-language articles from 1950 to February 2010 using the terms chronic non-cancer pain and opioids together and in combination with undertreatment, adherence, and compliance. Results: The majority of patients treated with traditional opioids experience gastrointestinal-or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. These side effects often lead to discontinuation of opioid therapy. Concerns about side effects, analgesic tolerance, dependence, and addiction limit the use of opioids for the management of chronic pain. Treatment with tapentadol appears to provide several advantages of an analgesic with a more favorable side-effect profile than the classic-opioid receptor agonist oxycodone (especially related to gastrointestinal tolerability). Conclusions: The pervasiveness of opioid-associated side effects and concerns related to tolerance, dependence, and addiction present potential barriers to the approval and use of opioids for the management of chronic non-cancer pain. The lower incidence of opioid-associated adverse events and possibly fewer withdrawal symptoms, combined with a satisfactory analgesic profile associated with tapentadol, suggest its potential utility for the management of chronic non-cancer pain. This review will focus on the incidence of opioid-related side effects and barriers to opioid therapy that are available as English-language articles in the MEDLINE index, and as such, it is a representative but not an exhaustive review of the current literature.

Original languageEnglish
Pages (from-to)1677-1684
Number of pages8
JournalCurrent Medical Research and Opinion
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Opioid Analgesics
Pain
Analgesics
tapentadol
MEDLINE
Incidence
Language
Central Nervous System
Oxycodone
Substance Withdrawal Syndrome
Opioid Receptors
Constipation
Pain Management
Therapeutics
Chronic Pain
Nausea
Compliance
Substance-Related Disorders
Norepinephrine
Physicians

Keywords

  • Opioid analgesics
  • Refractory pain
  • Tapentadol
  • Treatment failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{c42743ab20c24a988357caf76ddf3f03,
title = "Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: Tapentadol, a step toward a solution",
abstract = "Objective: Opioids are among the most effective and potent analgesics currently available. Their utility in the management of pain associated with cancer, acute injury, or surgery is well recognized. However, extending the application of opioids to the management of chronic non-cancer pain has met with considerable resistance. This resistance is due in part to concerns related to gastrointestinal and central nervous system-related adverse events as well as issues pertaining to regulatory affairs, the development of tolerance, incorrect drug usage, and addiction. This review focuses on the incidence of opioid-related side effects and the patient and physician barriers to opioid therapy for chronic non-cancer pain. Tapentadol, a centrally acting analgesic with two mechanisms of action,-opioid agonism and norepinephrine reuptake inhibition, may be considered to be a partial solution to some of these issues. Methods: MEDLINE was searched for English-language articles from 1950 to February 2010 using the terms chronic non-cancer pain and opioids together and in combination with undertreatment, adherence, and compliance. Results: The majority of patients treated with traditional opioids experience gastrointestinal-or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. These side effects often lead to discontinuation of opioid therapy. Concerns about side effects, analgesic tolerance, dependence, and addiction limit the use of opioids for the management of chronic pain. Treatment with tapentadol appears to provide several advantages of an analgesic with a more favorable side-effect profile than the classic-opioid receptor agonist oxycodone (especially related to gastrointestinal tolerability). Conclusions: The pervasiveness of opioid-associated side effects and concerns related to tolerance, dependence, and addiction present potential barriers to the approval and use of opioids for the management of chronic non-cancer pain. The lower incidence of opioid-associated adverse events and possibly fewer withdrawal symptoms, combined with a satisfactory analgesic profile associated with tapentadol, suggest its potential utility for the management of chronic non-cancer pain. This review will focus on the incidence of opioid-related side effects and barriers to opioid therapy that are available as English-language articles in the MEDLINE index, and as such, it is a representative but not an exhaustive review of the current literature.",
keywords = "Opioid analgesics, Refractory pain, Tapentadol, Treatment failure",
author = "Candiotti, {Keith A} and Gitlin, {Melvin C.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1185/03007995.2010.483941",
language = "English",
volume = "26",
pages = "1677--1684",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain

T2 - Tapentadol, a step toward a solution

AU - Candiotti, Keith A

AU - Gitlin, Melvin C.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objective: Opioids are among the most effective and potent analgesics currently available. Their utility in the management of pain associated with cancer, acute injury, or surgery is well recognized. However, extending the application of opioids to the management of chronic non-cancer pain has met with considerable resistance. This resistance is due in part to concerns related to gastrointestinal and central nervous system-related adverse events as well as issues pertaining to regulatory affairs, the development of tolerance, incorrect drug usage, and addiction. This review focuses on the incidence of opioid-related side effects and the patient and physician barriers to opioid therapy for chronic non-cancer pain. Tapentadol, a centrally acting analgesic with two mechanisms of action,-opioid agonism and norepinephrine reuptake inhibition, may be considered to be a partial solution to some of these issues. Methods: MEDLINE was searched for English-language articles from 1950 to February 2010 using the terms chronic non-cancer pain and opioids together and in combination with undertreatment, adherence, and compliance. Results: The majority of patients treated with traditional opioids experience gastrointestinal-or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. These side effects often lead to discontinuation of opioid therapy. Concerns about side effects, analgesic tolerance, dependence, and addiction limit the use of opioids for the management of chronic pain. Treatment with tapentadol appears to provide several advantages of an analgesic with a more favorable side-effect profile than the classic-opioid receptor agonist oxycodone (especially related to gastrointestinal tolerability). Conclusions: The pervasiveness of opioid-associated side effects and concerns related to tolerance, dependence, and addiction present potential barriers to the approval and use of opioids for the management of chronic non-cancer pain. The lower incidence of opioid-associated adverse events and possibly fewer withdrawal symptoms, combined with a satisfactory analgesic profile associated with tapentadol, suggest its potential utility for the management of chronic non-cancer pain. This review will focus on the incidence of opioid-related side effects and barriers to opioid therapy that are available as English-language articles in the MEDLINE index, and as such, it is a representative but not an exhaustive review of the current literature.

AB - Objective: Opioids are among the most effective and potent analgesics currently available. Their utility in the management of pain associated with cancer, acute injury, or surgery is well recognized. However, extending the application of opioids to the management of chronic non-cancer pain has met with considerable resistance. This resistance is due in part to concerns related to gastrointestinal and central nervous system-related adverse events as well as issues pertaining to regulatory affairs, the development of tolerance, incorrect drug usage, and addiction. This review focuses on the incidence of opioid-related side effects and the patient and physician barriers to opioid therapy for chronic non-cancer pain. Tapentadol, a centrally acting analgesic with two mechanisms of action,-opioid agonism and norepinephrine reuptake inhibition, may be considered to be a partial solution to some of these issues. Methods: MEDLINE was searched for English-language articles from 1950 to February 2010 using the terms chronic non-cancer pain and opioids together and in combination with undertreatment, adherence, and compliance. Results: The majority of patients treated with traditional opioids experience gastrointestinal-or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. These side effects often lead to discontinuation of opioid therapy. Concerns about side effects, analgesic tolerance, dependence, and addiction limit the use of opioids for the management of chronic pain. Treatment with tapentadol appears to provide several advantages of an analgesic with a more favorable side-effect profile than the classic-opioid receptor agonist oxycodone (especially related to gastrointestinal tolerability). Conclusions: The pervasiveness of opioid-associated side effects and concerns related to tolerance, dependence, and addiction present potential barriers to the approval and use of opioids for the management of chronic non-cancer pain. The lower incidence of opioid-associated adverse events and possibly fewer withdrawal symptoms, combined with a satisfactory analgesic profile associated with tapentadol, suggest its potential utility for the management of chronic non-cancer pain. This review will focus on the incidence of opioid-related side effects and barriers to opioid therapy that are available as English-language articles in the MEDLINE index, and as such, it is a representative but not an exhaustive review of the current literature.

KW - Opioid analgesics

KW - Refractory pain

KW - Tapentadol

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=77953577261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953577261&partnerID=8YFLogxK

U2 - 10.1185/03007995.2010.483941

DO - 10.1185/03007995.2010.483941

M3 - Article

VL - 26

SP - 1677

EP - 1684

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 7

ER -